Transgene

Transgene Net Change in Cash

The Net Change in Cash of Transgene (TNG.PA) as of Nov 19, 2026 is 1.00 M EUR. In the previous year, Net Change in Cash was 11.26 M EUR — a change of -91.09% (lower).

Net Change in Cash

1.00 MEUR

YoY

-91.09%

Last updated:

Net Change in Cash of Transgene is 2024 1.00 M EUR. Net Change in Cash of Transgene was 2023 11.26 M EUR. It decreases by -91.09% lower compared to the previous year.

The Transgene Net Change in Cash history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Change in Cash
Date
Net Change in Cash
Jan 1, 2017
-3.21 M EUR
Jan 1, 2018
242,000.00 EUR
Jan 1, 2019
-542,000.00 EUR
Jan 1, 2020
3.93 M EUR
Jan 1, 2021
634,000.00 EUR
Jan 1, 2022
-1.51 M EUR
Jan 1, 2023
11.26 M EUR
Jan 1, 2024
1.00 M EUR
The Transgene Net Change in Cash history
YEARNet Change in CashYoY
1.00 MEUR-91.09%
11.26 MEUR-846.88%
-1.51 MEUR-337.85%
634,000.00EUR-83.88%
3.93 MEUR-825.83%
-542,000.00EUR-323.97%
242,000.00EUR-107.53%
-3.21 MEUR-304.59%
1.57 MEUR-788.60%
-228,000.00EUR-85.97%
-1.63 MEUR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Transgene Stock analysis

What does Transgene do? Transgene SA is a French biotechnology company specializing in the development and production of therapeutics, with a focus on cancer medications. It has a strong patent portfolio in the field of viral vectors, which are used for targeted gene therapy. The company's main areas of operation are clinical trials, research, and production. Transgene has research and production facilities in Strasbourg and Lyon, with over 100 employees. It has established partnerships with pharmaceutical companies, including Takeda Pharmaceuticals, for the development and marketing of therapeutics. Its flagship product, OncoVir-1®, is an immunomodulator that stimulates the immune system to fight tumor cells. Another promising product is TG4010, a therapeutic vaccine for non-small cell lung carcinoma. Transgene is an emerging company with a promising portfolio of cancer therapeutics, leveraging its expertise in viral vectors and collaborating closely with industry partners to expedite the development of marketable products. Transgene is expected to play a significant role in the development of new and innovative cancer treatments. Transgene is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Transgene stock

Net Change in Cash of Transgene is 1.00 M EUR in 2024.

Net Change in Cash of Transgene changed from 11.26 M EUR to 1.00 M EUR, representing a -91.09% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Change in Cash Transgene since 2006 – with annual values, charts, and detailed analysis.

Net change in cash is the total change in cash and equivalents during the period, combining operating, investing, and financing cash flows.

Net Change in Cash's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Change in Cash's Transgene historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Transgene

All Key Metrics — Transgene